EAM
KERX

EverPoint Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

EverPoint Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$352K Buy
+60,000
New +$328K 0.01% 392
2015
Q2 		– Sell
-250,000
Closed -$3.18M – 653
2015
Q1 		$3.18M Buy
+250,000
New +$3.21M 0.06% 358

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EverPoint Asset Management's KERX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Keryx Biopharmaceuticals Inc (KERX) in Q4 2016: 60,000 shares worth $352K. The stake represents 0.01% of the portfolio and ranks #392 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in KERX as recently as Q1 2015.

EverPoint Asset Management first reported a position in KERX in Q1 2015 and has held it in 2 quarters since. The position peaked at $3.18M in Q1 2015. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

  • EverPoint Asset Management held 60,000 shares of Keryx Biopharmaceuticals Inc worth $352K as of Q4 2016.
  • Keryx Biopharmaceuticals Inc was a new EverPoint Asset Management position in Q4 2016.
  • Keryx Biopharmaceuticals Inc made up 0.01% of EverPoint Asset Management's portfolio in Q4 2016, its #392 holding.
  • EverPoint Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and has held it in 2 quarters since.
  • EverPoint Asset Management's Keryx Biopharmaceuticals Inc position peaked at $3.18M in Q1 2015.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.